Your browser doesn't support javascript.
loading
Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes.
Kenney, Patrick A; Vikram, Raghunandan; Prasad, Srinivasa R; Tamboli, Pheroze; Matin, Surena F; Wood, Christopher G; Karam, Jose A.
Afiliação
  • Kenney PA; Department of Urology, Yale School of Medicine, New Haven, CT, USA.
  • Vikram R; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Prasad SR; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tamboli P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Matin SF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wood CG; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Karam JA; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
BJU Int ; 116(1): 85-92, 2015 Jul.
Article em En | MEDLINE | ID: mdl-25395040
ABSTRACT

OBJECTIVE:

To characterise the clinical, radiological and histological features of mucinous tubular and spindle cell carcinoma (MTSCC), as well as oncological outcomes. PATIENTS AND

METHODS:

This is a single institution retrospective analysis of all patients with MTSCC from 2002 to 2011. Patients were excluded if MTSCC could not be confirmed on pathology re-review (four patients). Clinical characteristics, pathology, imaging, and outcomes were reviewed for the 19 included patients.

RESULTS:

The median (range) age at diagnosis was 59 (17-71) years with a female predominance (78.9%). On contrast-enhanced computed tomography, MTSCC enhanced less than the cortex during the corticomedullary phase. The mean (range) tumour attenuation was 36 (24-48), 67 (41-133), 89 (49-152), and 76 (52-106) Hounsfield units in the pre-contrast, corticomedullary, nephrographic and excretory phases, respectively. In all, 16 patients were treated with partial (five patients) or radical nephrectomy (11) for pT1 (62.5%), pT2 (31.3%), and pT3a disease (6.3%). One patient underwent active surveillance. Of three patients (13.0%) managed with energy ablation, there was one recurrence that was treated with salvage surgery. One patient (5.3%) had metastatic disease at diagnosis and died from disease 64.7 months later. A patient with a pT2bN0M0 MTSCC with sarcomatoid dedifferentiation developed bone metastases 9.5 months after diagnosis and was alive at 19.0 months. The remainder were free of recurrence or progression.

CONCLUSION:

MTSCC is a rare renal cell carcinoma (RCC) variant. In this largest series to date, MTSCC presented at a broad range of ages and displayed a female predilection. Imaging and pathological features of MTSCC display some overlap with papillary RCC. MTSCC is associated with excellent outcomes overall, but is not universally indolent.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Adenocarcinoma Mucinoso / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BJU Int Assunto da revista: UROLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Adenocarcinoma Mucinoso / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BJU Int Assunto da revista: UROLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos